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http://www.biomedcentral.com/1471-2407/14/426RESEARCH ARTICLE Open AccessCelecoxib increases miR-222 while deterring
aromatase-expressing breast tumor growth
in mice
Tsz Yan Wong1†, Fengjuan Li2†, Shu-mei Lin5, Franky L Chan3, Shiuan Chen4 and Lai K Leung1,2*Abstract
Background: Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is
effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that use
of cyclooxygenase (COX) inhibitors is associated with reduced breast cancer risk.
Methods: In the present study, we employed an established mouse model for postmenopausal breast cancer to
evaluate the potential mechanisms of the COX-2 inhibitor celecoxib. Aromatase-expressing MCF-7 cells were
transplanted into ovariectomized athymic mice. The animals were given celecoxib at 1500 ppm or aspirin at
200 ppm by oral administration with androstenedione injection.
Results: Our results showed that both COX inhibitors could suppress the cancer xenograft growth without
changing the plasma estrogen level. Protein expression of ERα, COX-2, Cyclin A, and Bcl-xL were reduced in
celecoxib-treated tumor samples, whereas only Bcl-xL expression was suppressed in those treated with aspirin.
Among the breast cancer-related miRNAs, miR-222 expression was elevated in samples treated with celecoxib.
Further studies in culture cells verified that the increase in miR-222 expression might contribute to ERα
downregulation but not the growth deterrence of cells.
Conclusion: Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by
regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis. Besides, celecoxib might
affect miR expression in an undesirable fashion.
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Cyclooxygenase (COX) or prostaglandin G/H endoper-
oxide synthase is the enzyme responsible for converting
arachidonic acid into prostaglandins [1]. Two isozymes
of COX with differential expression patterns have been
identified. COX-1 is constitutively expressed, and is in-
volved in normal physiological functions, such as vas-
cular homeostasis, platelet aggregation, gastric mucosa
protection and maintenance of renal blood flow [2]. In* Correspondence: laikleung@cuhk.edu.hk
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unless otherwise stated.contrast, COX-2 expression can be induced by cytokines
and growth factors. This implies that COX-2 has a greater
involvement in inflammation and cancer development than
COX-1 [3]. Studies have shown that COX-2 is expressed in
breast cancer tissues but not in normal breast tissues [4,5].
The concentrations of prostaglandin E2 (PGE2) in tumor
and metastatic tissues are also higher than those in normal
tissues [6]. The significance of COX-2 in breast carcino-
genesis has also been described in different levels of re-
search. Over-expressing COX-2 in mice promotes breast
cancer development [7], whereas the administration of
COX-2 inhibitor could prevent against breast carcinogen-
esis [8-10].
Aspirin is a non-steroidal anti-inflammatory drug
(NSAID) that inhibits both COX-1 and COX-2. It is cap-
able of deterring the growth of breast cancer cells [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 List of primers designed for RT-PCR quantitation
Forward primer sequence Reverse primer sequence
MYC 5′-TCT TCC AGA TAT CCT
CGC TG-3′
5′-TAT GAC CTC GAC TAC GAC
TCG-3′
E2F2 5′-TTA CAG TCA GAG GCC
TGG CT-3′
5′-TTC TAA TAC TCA TCC CTG
TTT TTC C-3′
GAPDH 5′-GAG TCA ACG GAT TTG
GTC GT-3′
5′-GAT CTC GCT CCT GGA AGA
TG-3′















































Figure 1 Celexoxib or aspirin treatment had no effect on body
weight and liver weight. Mice were inoculated with MCF-7aro cells
and treated with celecoxib, aspirin and androstenedione. Their body
weight (A) was monitored from the second week after inoculation
and liver weight (B) was measured at the end of experiment. Groups
labeled as AD, AD+celecoxib, and AD+aspirin are the mice treated
with androstenedione, androstenedione and celecoxib, and
androstenedione and aspirin, respectively. Values are means ± SEMs,
n=6 to 8. The data was analyzed by One-way ANOVA, followed by
Tukey’s Multiple Comparison test when P<0.05.
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http://www.biomedcentral.com/1471-2407/14/426Regular use of aspirin after breast cancer diagnosis im-
proves survival [12]. In contrast, celecoxib is a new NSAID
that specifically inhibits COX-2 and has drawn much at-
tention for its anti-cancer properties. The COX-2 inhibitor
reduces mammary tumor incidence induced by DMBA
in rats [13]. It is also effective in blocking the growth of
breast cancer xenografts in nude mice [14]. Celecoxib
could evoke cell cycle arrest, anti-angiogenesis [15], and
apoptotic cell death [16,17] in cancers. Although these
NSAIDs appear to be chemopreventive, side effects like
gastrointestinal tract bleeding [18] and cardiovascular tox-
icity [19] have been reported.
MicroRNAs (miRNAs) are small noncoding RNAs of
about 22 nucleotides (nt) in length, and they can regulate
gene expression at the post-transcriptional level. These
single-stranded miRNAs bind to the 3′ untranslated re-
gion (3′ UTR) of target mRNAs, and cause translation
blockage and/or mRNA degradation [20]. Studies have
shown that miRNAs may regulate biological processes,
like differentiation [21], cell growth and death [21], and
tumorigenesis [22,23]. Many miRNAs are under-expressed
in human tumors compared to normal tissues [24].
The objective of this study was to determine differential
gene expression and other potential growth-suppressing
mechanisms in breast tumorigenesis after celecoxib and
aspirin treatment. We hypothesized that aromatase activ-
ity and miRNA regulation could be differentially inhibited
by the two NSAIDs.
Methods
Celecoxib was a gift from Pfizer Corp. Hong Kong Ltd.
Aspirin was obtained from Sigma Chemical Co. (St. Louis,
MO). Other chemicals were ordered from Sigma Chemical,
if not stated.
Cell culture
MCF-7 cells stably transfected with human CYP19 (MCF-
7aro) were prepared as previously described [25]. These
cells were maintained in MEM medium (Invitrogen, Grand
Island, NY) supplemented with 10% fetal bovine serum
(Invitrogen Life Technology, Rockville, MD) and the selec-
tion antibiotic G418 (500 μg/ml, USB, Cleveland, OH).
They were incubated at 37°C in 5% carbon dioxide and
routinely sub-cultured when reaching 80% confluency.
Part I. Animal experiment
This mouse model for postmenopausal breast carcinogen-
esis was described by Yue et al. [26]. Six-week old female
athymic mice were acquired from the Animal Facility of
Chinese University of Hong Kong. These mice were ovari-
ectomized and allowed 3 weeks to recover, and were fed
purified phytoestrogen-free AIN-93G diet. They were
transplanted with MCF-7aro cells and randomly assigned
into 4 regimens: control mice (Control), mice injectedwith androstenedione (AD), mice injected with andro-
stenedione and treated with celecoxib (AD + celecoxib)
and mice injected with androstenedione and treated
with aspirin (AD + aspirin). The AD, AD + celecoxib
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Figure 2 Effect of celecoxib and aspirin on the growth of MCF-7aro xenograft. Mice were inoculated with MCF-7aro cells at 2 sites per
mouse after ovariectomy. They were injected subcutaneously with androstenedione every day starting on the next day after inoculation. Tumor
volumes (A) were estimated once a week from Day 7 after inoculation. Day labeled as (*) was the time when AD Group significantly deviated
from Control Group sacrifice. (**) was the day when tumor volumes of AD+Celecoxib and AD+Aspirin started deviated from that of AD.
The tumor weight was measured at the day of sacrifice (B). Groups labeled as AD, AD+celecoxib, and AD+aspirin are the mice treated with
androstenedione, androstenedione and celecoxib, and androstenedione and aspirin, respectively. Values are means ± SEM, n=6 to 8
(2 inoculation sites combined as one data point). The data was analyzed by One-way ANOVA, followed by Tukey’s Multiple Comparison test
when P<0.05. Means labeled with different letters are significantly different (order: b>a).
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http://www.biomedcentral.com/1471-2407/14/426androstenedione (0.1 mg dissolved in 0.1 ml 0.3% hydroxyl
propyl cellulose). Control mice received the carrier solvent
injection only. Celecoxib and aspirin were administered in
the diet at 1500 ppm and 200 ppm, respectively. Before
transplantation, MCF-7aro cells were maintained in a cul-
ture incubator as described above. The cells were trypsi-
nized and suspended in matrigel matrix (BD Biosciences,San Jose CA) (10 mg/ml) at 3 × 107 cells/ml. One hundred
μl of cells were injected into the two flanks of the animal.
This experiment was approved by Department of Health,
the Governemnt of the Hong Kong SAR (Ref (07–164)
in DH/ORHI/8/2/1 pt.9), and Animal Experimentation














































































































Figure 3 (See legend on next page.)
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Figure 3 Effect of celecoxib and aspirin on plasma estradiol concentration, uterine weight and ERα expression. Blood was drawn from
the animals at sacrifice. Serum estradiol concentration was quantified by ELISA (A). Sample labeled as AD is androstenedione. Uterine of the
experimental animals were dissected and weighed at sacrifice as shown in B. Western blot analysis of ERα in xenograft samples was analyzed
by immunoblotting (C) and the optical density measurements were shown in the lower panel. Groups labeled as AD, AD+celecoxib, and AD+aspirin
are the mice treated with androstenedione, androstenedione and celecoxib, and androstenedione and aspirin, respectively. Values are means ± SEM,
n=6 to 8.The data was analyzed by One-way ANOVA, followed by Tukey’s Multiple Comparison test when P<0.05. Means labeled with different letter
are significantly different (order: b>a).
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http://www.biomedcentral.com/1471-2407/14/426The body weight, tumor size and food intake were
monitored weekly throughout the study. Tumor volumes
were measured by an electronic caliper and estimated
according to the formula: π/6 × length × width × height,
where length, width, and height were the three orthog-
onal diameters of the tumors. At the end of the study,
the mice were euthanized by cervical dislocation. Livers
and uteri were weighed. Tumors and serum were col-
lected and stored at −80°C until assayed.Quantitative real time PCR assay
The frozen tumor samples were pulverized in a Dounce
homogenizer with liquid nitrogen. Total RNA was ex-
tracted from the sample using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The concentration and purity of RNA
were determined by absorbance measured at 260/280 nm.
First DNA strands were synthesized from 3 μg total RNA
using 5× primers (Assay-on-Demand™, Applied Biosystems,
Foster City, CA, USA) and MMLV reverse transcriptase
(USB Corporation, Cleveland, OH, USA). Target fragments
were quantified by DNA Engine Opticon II (MJ Research,
Inc., Waltham, MA). Probes for amplification were ob-
tained from Assay-on-Demand™, Applied Biosystems,
i.e. the housekeeping U6 snRNA (Assay ID: 001973), has-
miR-let-7c (Assay ID: 000379), has-miR-Let-7 g (Assay
ID: 002282), has-miR-98 (Assay ID: 000577), has-miR-221
(Assay ID: 000524), has-miR-222 (Assay ID: 002276),
has-miR-17-5P (Assay ID: 000393), has-miR-101 (Assay
ID: 002253), has-miR-145 (Assay ID: 002278). We used
the Real-time PCR Taqman Universal PCR Master Mix
(Applied Biosystems) to set up the PCR reactions as de-
scribed in the manual. Signals obtained from U6 were uti-
lized for normalization, and relative gene expression were
analyzed by using the 2−ΔΔCΤ method [27].
For the determination of MYC and E2F2 RNA expres-
sion, we used oligo-dT primers for the first strand synthe-
sis, SYBR green PCR Master Mix Reagent kit (Applied
Biosystems) for the reaction setup, and GAPDH for
normalization. The gene-amplification primer sequences
were shown as below. By analyzing the dissociation curves
and gel images, these primers did not produce non-
specific amplifications. The relative gene expression was
also determined by the 2-ΔΔCT method (see Table 1).Immunoblot of proteins extracted from MCF-7aro tumors
The frozen samples were pulverized in a Dounce
homogenizer with added liquid nitrogen. The pulverized
samples were then sonicated in lysis buffer (PBS, 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS, 40 mg/L PMSF,
0.5 mg/L aprotinin, 0.5 mg/L leupeptin, 1.1 mmol/L EDTA
and 0.7 mg/L pepstatin) with a cell disruptor (Branson Ul-
trasonics Corp., Danbury, CT, U.S.A.) on ice for 30 s for
protein extraction. Thirty μg of protein extract were sepa-
rated on 10% SDS-PAGE and transferred onto an Immobi-
lon PVDF membrane (Millipore, Bedford, MA). Anti-ERα,
anti-COX-2, anti-CDK4, Cyclin A, E, anti-Bcl-xL, Bcl-2,
Bax, Bak (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and anti-β-actin primary (Sigma Chem) and second-
ary antibodies conjugated with horseradish peroxidase
(Santa Cruz Biotechnology) were used for protein de-
tection. The targeted proteins were visualized by autora-
diography on a Biomax (Kodak®) film. The images were
scanned and analyzed for optical density by using the com-
puter software ImageJ (National Institute of Mental Health,
Bethesda MD, USA).Serum estradiol determination
Serum estradiol concentration was measured by using
ELISA kits from Cayman Chemical Company (Ann Arbor,
MI). The samples were added into a 96-well plate coated
with antibody raised against estradiol. After incubating with
the tracer and developing at room temperature, the absorb-
ance was quantified using a microplate reader (FluroStar®,
BMG Labtechnologies GmBH, Offenburg, Germany). The
amount of estradiol could be read against a standard curve
constructed with the hormone provided in the kit.Part II. In vitro experiments
CYP19 enzyme inhibition assay
Two pmol recombinant aromatase protein (human CYP19
Supersomes®, BD Gentest, Woburn, MA) was incubated
with celecoxib or aspirin in the substrate-containing assay
buffer (25 nM-[1β-3H(N)] androst-4-ene-3,17-dione (NET-
926; Perkin-Elmer Life and Analytical Sciences, Boston,
MA), 3 · 3 mM-MgCl2, 100 mM-KH2PO4 (pH 7 · 4)). The
reaction was initiated by adding 1.3 mM-NADPH and in-













































































































































































Figure 4 (See legend on next page.)
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Figure 4 Protein expression of COX-2 and genes related to cell cycle and apoptosis. COX-2, cell cycle and apoptosis regulatory proteins
were determined by western blot analysis, and the image is shown in A. The corresponding optical density reading is shown in B. Groups labeled
as AD, AD+celecoxib, and AD+aspirin are the mice treated with androstenedione, androstenedione and celecoxib, and androstenedione and
aspirin, respectively. Values are means ± SEM, n=3 to 5. The data was analyzed by One-way ANOVA, followed by Tukey’s Multiple Comparison test
when P<0.05. Means labeled with different letter are significantly different (order: b>a).
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10 min at 4°C. The aqueous phase was transferred into a
tube containing 500 μl of 5% activated charcoal. An aliquot
of the supernatant was removed for scintillation counting
after incubating for 30 min.Verification of expression pattern in culture cells
MCF-7aro cells were seeded in culture dishes at 5 × 102
cells/mm2, and allowed to settle for 1 day before treat-
ment began. They were co-treated with androstenedione
and various concentrations of aspirin or celecoxib for
1–3 days with DMSO as the carrier solvent. The final
concentration of solvent was 0.1% (vol/vol). Total pro-
tein or RNA was extracted and analyzed.Relationship between the differentially expressed genes and
miR-222/-98
MCF-7aro cells were cultured in OptiMEM (Invitrogen
Life Technology) and transfected with miR-222 or miR-98
mimics (Invitogen Life Technology) in Lipofectamine 2000
(Invitrogen Life Technology). Six hr after the transfection,
the culture medium was replaced with RPMI (phenol red
free) supplemented with 10nM androstenedione and 5%
charcoal-dextran treated fetal bovine serum (Biotechnics
Research, CA USA). Total protein or RNA was extracted
72 hr after the medium change. MTT assays were also per-
formed in separate experiments to investigate the effect on
cell growth.Statistical methods
The software package Prism® 5.0 (GraphPad Software, Inc.,
CA, USA) was employed for statistical analysis. For mul-
tiple group analysis, the data were analyzed by One-way
ANOVA followed by Tukey’s Multiple Comparison if sig-
nificant differences (P < 0.5) were observed.Results
Celecoxib and aspirin treatment had no effect on mouse
body weight and liver weight
The body weights of all mice gradually increased and no
significant differences were observed among the groups
at any given time point (Figure 1A). Similar to the body
weights, no significant differences were observed in liver
weights at euthanasia (Figure 1B). The drug treatment
appeared to be within the tolerable limit.Effect of celecoxib and aspirin on xenograft growth
Accelerated tumor growth was recorded in mice treated
with androstenedione (AD) as compared with that of Con-
trol. Tumor volume in AD mice became significantly
(P < 0.05) different from that in Control starting from Day
35 until sacrifice. Beginning from Day 84 until euthanasia,
tumor volumes in the treatment groups AD+ celecoxib
and AD+ aspirin were significantly (P < 0.05) smaller than
those in AD mice (Figure 2A). The tumor weights mea-
sured at euthanasia were consistent with the tumor vol-
ume data (Figure 2B).
Celecoxib decreased ERα expression without affecting
plasma estradiol concentration and uterine weight
All mice received androstenedione had higher plasma es-
tradiol concentrations than those in Control mice. No re-
duction in estradiol was observed in mice treated with
celecoxib or aspirin (Figure 3A). AD mice exhibited a two-
fold increase in uterine wet weight over that of Control.
Treatment with celecoxib or aspirin did not signifi-
cantly change the androstenedione-induced uterine weight
(Figure 3B). The uterine weight data were consistent with
the plasma estrogen concentrations. The androstenedione-
induced expression of ERα, on the other hand, was re-
versed by celecoxib administration (Figure 3C).
Expression of COX-2, cell cycle and apoptosis-related
proteins in tumors
Since both celecoxib and aspirin inhibited tumor growth
in the animal model, we examined some proteins that are
important in regulating cell growth. COX-2, Cyclin A & E,
Bcl-2, and Bcl-xL were higher in AD tumor samples than
those in the Control as shown in Figure 4. Both NSAIDs
counteracted the androstenedione-induced Bcl-xL, while
celecoxib could also neutralize the induced expression
of COX-2 and Cyclin A. Other proteins (CDK4, Bax, and
Bak) were not different among all treatment groups.
MiRNA expression in tumors
Expression of breast cancer-associated miRNAs, including
miR-let-7c, miR-let-7 g, miR-98, miR-221, miR-222, miR-
101, miR-145 and miR-17-5p, in the xenografts was also
measured. Among these, miR-98 (Figure 5A) and miR-222
(Figure 5B) were downregulated in AD mice. Aspirin and
celecoxib could reverse the suppression of miR-98 and
miR-222, respectively. Although the expression of miR-145








































































































Figure 5 MiRNA expression in tumors in mice treated with
celecoxib and aspirin. Total mRNA was extracted from tumors and
miRNA expression of miR-98 (A), 222 (B), 145 (C) was quantified by
real-time PCR. Groups labeled as AD, AD+celecoxib, and AD+aspirin
are the mice treated with androstenedione, androstenedione and
celecoxib, and androstenedione and aspirin, respectively. Values are
means ± SEM, n = 6. The data was analyzed by One-way ANOVA,
followed by Tukey’s Multiple Comparison test when P<0.05. Means



































































Figure 6 The effect of drug treatment on c-Myc and E2F2 in
tumors. Total mRNA was extracted from tumors and mRNA
expression level of c-Myc (A) and E2F2 (B) was quantified by
real-time PCR. Groups labeled as AD, AD+celecoxib, and AD+aspirin
are the mice treated with androstenedione, androstenedione and
celecoxib, and androstenedione and aspirin, respectively. Values are
means ± SEM, n = 6.The data was analyzed by One-way ANOVA,
followed by Tukey’s Multiple Comparison test when P<0.05. Means
labeled with different letter are significantly different (order: b>a).
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http://www.biomedcentral.com/1471-2407/14/426tended to increase its level (Figure 5C). No significant
changes were found in the expression of the other miR-
NAs (data not shown).
MYC and E2F2 mRNA expression in tumors
A recent study has documented that MYC and E2F2 can
be regulated by miR-98 [28]. The mRNA expression of
MYC and E2F2 was examined as a follow-up study to
the differential expression of miR-98 as shown above.
Our results showed that the mRNA expression of MYC
could be induced by androstenedione, but celecoxib and
aspirin treatment had no counteracting effect on the ex-
pression (Figure 6A). No differences were found in the
mRNA expression of E2F2 (Figure 6B).
Celecoxib and aspirin were not aromatase inhibitors
Celecoxib (1–10 μM) and aspirin (1–1000 μM) had no in-
hibition on the aromatase activity of CYP19 recombinant
protein (data not shown). These results were consistent
with the null effect on plasma estrogen in mice.
Verification of protein expression in the cell culture
system
Immunoblot results indicated that 10 nM androstene-
dione elevated the protein levels of Bcl-xL, Cyclin A, and
Cox-2 and suppressed that of ERα. Celecoxib furtherA 
B 
Figure 7 Verification of protein expression in the cell culture system.
cells were cultured and treated with 10 nM androstenedione and aspirin or ce
(A) is the image for aspirin-treated samples and celecoxib-treated samples aresuppressed ERα, and reduced the steroid-induced Bcl-xL,
Cyclin A, and Cox-2 levels in the cultured MCF-7aro cells
in a dose-dependent manner (Figure 7B). In contrast, as-
pirin did not affect any of those proteins in the culture
system (Figure 7A). The results for celecoxib were consist-
ent to those in the animal study.
MiR-222 expression was induced by celecoxib in MCF-
7aro cells in vitro
By using real-time PCR assay, we determined the expres-
sion of miR-222/-98 in cells treated with celecoxib and
aspirin. Compared to the control, androgen administration
suppressed the expression of miR-222 and miR-98. Ten
μM celecoxib significantly (P < 0.05) reversed the sup-
pression of miR-222 (Figure 8A), whereas no significant
changes were observed for miR-98 (Figure 8C) or those
cultures treated with aspirin (Figure 8B & D).
MiR-222 could be a factor for ERα suppression
In order to investigate the connection between miR-
222/-98 and the protein expression profile, MCF-7aro
cells were transfected with mimic miR-222 and miR-98.
Androstenedione could reduce ERα. The miR-222 mimic
further lowered the ERα protein, while other proteins
tested were not affected. MiR-98 had no effect on any of
the proteins (Figure 9). The administration of miR-222Western blot analysis was performed on a cell culture system. MCF-7aro
lecoxib for 72 hr. Protein was extracted from the cells. The upper panel
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Figure 8 MiR-98 and miR-222 expression in MCF-7aro cells treated with aspirin and celecoxib. Cells are treated with androstenedione and
celecoxib, and androstenedione and aspirin. Total mRNA was extracted from cells and miRNA expression of miR-98 and 222 was quantified by
real-time PCR. MiR-222 expression of celecoxib and aspirin are shown in A & B, while C & D are the miR-98 expression of celecoxib and aspirin,
respectively. Values are means ± SEM, n = 3. The data was analyzed by One-way ANOVA, followed by Tukey’s Multiple Comparison test when
P<0.05. Means labeled with different letters are significantly different (order: c>b>a).
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http://www.biomedcentral.com/1471-2407/14/426inhibitor did not change ERα expression compared with
that of miR-222 inhibitor –ve control. The low baseline
level of miR-222 could be the contributing factor. MTT
assays were also performed in these cultures. No signifi-
cant difference in cell growth was observed in cells
transfected with miR-222 or −98 mimic after 72-h incu-
bation (data not shown).Discussion
Previous studies have demonstrated that celecoxib at
high concentrations can suppress aromatase activity [29]
and reduce estradiol amount [30] in the cultured breast
cancer cells SK-BR-3 and MCF-7/Cox-2 clone. In the
present study, we could not validate the celecoxib’s in-
hibition on aromatase activity or expression in MCF-7
cells as high as 10 μM (data not shown). Furthermore,
the Cox-2 inhibitor was also not effective in lowering es-
tradiol concentration in an aromatase-expressing breastxenograft model. After all, neither celecoxib nor aspirin
were suppressors to aromatase at any levels.
Overexpression of cyclins has been observed in breast
cancer [31-33]. In contrast, celecoxib and aspirin inhibit
cell cycle progression through G1 phase arrest in colon
cancer cells [34,35]. In the present study, celecoxib but
not aspirin reduced the protein levels of Cyclin A. Since
the cyclin suppression is consistent with the condition
required for G-1 phase arrest, the COX-2 inhibitor might
block the cells from entering the S phase.
Apoptosis is a crucial process in the treatment of cancer.
COX-2 promotes resistance against apoptosis by altering
the levels of pro- and anti-apoptotic proteins [36,37]. Cele-
coxib induces apoptosis in breast cancer cells by differen-
tial regulation of Bcl-2 and Bax [38]. Aspirin is also able to
induce apoptosis by down-regulating Bcl-2 protein expres-
sion in colon cancer cells and human gastric epithelial
cells [39,40]. Rather than reducing Bcl-2, both celecoxib
and aspirin decreased Bcl-xL in the present study.
Figure 9 Protein expression in miR-98 and miR-222 over-expressed MCF-7aro cells. Cells are treated with androstenedione and transfected
with miR-98 or miR-222. Protein was extracted from cells and expression of ERa, Bcl-xL, Cyclin A, and Cox-2 was quantified by western blot. The
image represents one of two blots with similar results.
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http://www.biomedcentral.com/1471-2407/14/426Dysregulation of miRNAs has been demonstrated in
breast carcinogenesis, and their involvement in cancer
initiation and progression has been suggested [41,42].
MiR-98 may interact with and reduce the expression of
CYP19 [43], c-Myc and E2F2 [28] in cells. Increased miR-222
species is associated with drug resistance and estrogen-
independent growth [44]. MiR-145, on the other hand, is a
tumor suppressor gene and is down-regulated in MCF-7
cells [45]. Over-expressing miR-145 in breast cancer cells
suppresses the cell growth and induces apoptosis through
downregulating ERα and Rhotekin expression [46,47]. In
addition, miR-145 may also block the expression of Fli-1
and Bcl-2 in colon cancer cells [48]. Our study indicated
that androstenedione suppressed miR −98 and −222, and
aspirin and celecoxib reversed the expression in the tu-
mors, respectively. The null result of miR-98 expression in
cultures after aspirin treatment was inconsistent with the
animal study data. Aspirin could act indirect in controlling
miR-98. On the other hand, miR-222 was consistently up-
regulated by celecoxib administration in both in vivo and
in vitro systems. The interrelationship between miR-222
and ERα in the current study was not determined. The
induction of miR-222 expression might reduce ERα ex-
pression [49], or it could also be a direct result from
downregulation of ERα [50].Conclusion
In summary, both COX inhibitors suppressed breast tumor
growth. However, celecoxib might also upregulate the un-
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